CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector4597210.26442/22217185.2018.4.000013ArticlesСтатьиReview ArticleDiagnosis and the debatable issues of the treatment of heart failure with preserved ejection fractionДиагностика и спорные вопросы лечения сердечной недостаточности с сохраненной фракцией выбросаAkhilgovaZ. MАхильговаЗарина Макшариповна

аспирант

Zarina.akhilgova@mail.ruKurkinaM. VКуркинаМария Владимировнаmari.kurkina.1988@mail.ruDzhioevaZ. RДжиоеваЗарина Ройоновна

аспирант

zarisha_dzhioeva@mail.ruPuhaevaA. AПухаеваАлена Алексеевна

канд. мед. наук, доц.

alena_puhaeva@mail.ruAvtandilovA. GАвтандиловлександр Георгиевич

д-р мед. наук, проф., зав. каф. терапии и подростковой медицины

algav@mail.ruRussian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian FederationФГБОУ ДПО РМАНПО1512201894VOL 9, NO4 (2018)ТОМ 9, №4 (2018)323725092020Copyright ©; 2018, Eco-VectorCopyright ©; 2018, ООО "Эко-Вектор"2018Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://cardiosomatics.ru/2221-7185/article/view/45972

Heart failure with preserved fraction (HFpEF) amount for a half of the general heart failure and increasing progressively. In this review we discuss the issues of pathogenesis of HFpEF, illuminated in the recent literature in the last years. Considering the heterogeneity of the pathophysiology of this syndrome and the results of large-scale studies conducted nowadays, it considers the debatable treatment issues of the applying different drugs in the prevention of HFpEF.

Сердечная недостаточность с сохраненной фракцией выброса (СНсФВ) составляет 1/2 от общего числа случаев сердечной недостаточности и продолжает прогрессивно расти. В обзоре обсуждаются вопросы патогенеза СНсФВ, освещенные в современной литературе за последние годы. Учитывая гетерогенность патофизиологии данного синдрома и результаты проведенных на сегодняшний день крупных исследований, рассматриваются спорные вопросы применения разных лекарственных препаратов в профилактике осложнений и прогрессирования СНсФВ.

heart failure with preserved fractionpathophysiologypreventiontreatmentсердечная недостаточность с сохраненной фракцией выбросапатофизиологияпрофилактикалечениеESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 2016. Eur Heart J 2016; 37 (27): 2129-200.Upadhya B, Taffet G.E, Cheng C.P, Kitzman D.W. Heart Failure with Preserved Ejection Fraction in the Elderly: Scope of the Problem. J Mol Cell Cardiol 2015; 83: 73-87.Tribouilloy C, Rusinaru D, Mahjoub H et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008; 29 (3): 339-47.Zile M.R, Claggett B.L, Prescott M.F et. al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol 2016; 68 (22): 2425-36.Nanayakkara S, Patel H.C, Kaye D.M. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clin Med Insights Cardiol 2018; 12: 1179546817751609.Paulus W.J, Tschöpe C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation. J Am Coll Cardiol 2013; 62 (4): 263-71.Liu T, Song D, Dong J et al. Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. Front Physiol 2017, 8: 238.Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014; 15 (12): 786-801.Pries A.R, Badimon L, Bugiardini R. Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur Heart J 2015; 36 (45): 3134-46.An integrative translational approach to study heart failure with preserved ejection fraction: a posicion paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail 2018; 20 (2): 216-27.Levy B.I. How to Explain the Differences Between Renin Angiotensin System Modulators. Am J Hypertens 2005; 18 (S5): 134S-141S.Mohammed S.F, Hussain I, Abou Ezzeddine O.F et al. Right Ventricular Function in Heart Failure with Preserved Ejection Fraction: A Community Based Studу. Circulation 2014; 130 (25): 2310-20.Haykowsky M.J, Brubaker P.H, John J.M et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol Foundation 2011; 58 (3): 265-74.Brilla C.G, Funck R.C, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102 (12): 1388-93.Díez J, Querejeta R, López B et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105 (21): 2512-7.Yip G.W, Wang M, Wang T et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94 (5): 573-80.Zheng S.L, Chan F.T, Nabeebaccus A.A et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 2018; 104 (5): 407-15.Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H et al. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 2013; 99 (5): 320-6.Mak G.J, Ledwidge M.T, Watson C.J et. al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54 (18): 1674-82.Deswal A, Richardson P, Bozkurt B et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17 (8): 634-42.Lu Fang, Murphy A.J, Dart A.M. A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease. Front Pharmacol 2017; 8: 186.Ganado P, Ruiz E, Del Rio M et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. Eur J Pharmacol 2001; 428 (1): 19-27.Carretta R, Fabris B, Bardelli M et al. Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. J Hum Hypertens 1988; 2 (3): 171-5.Antoniades C, Bakogiannis C, Leeson P et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124 (3): 335-45.Koh K.K, Han S.H, A.H.N J.Y et al. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 2009; 133 (1): 23-31.De Ciuceis C, Salvetti M, Paini A et al. Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension. Intern Emerg Med 2017; 12 (7): 963-74.Solomon S.D, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380 (9851): 1387-95.Guazzi M, Vicenzi M, Arena R. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year studу. Circulation 2011; 124 (2): 164-74.Redfield M.M, Chen H.H, Borlaug B.A et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309 (12): 1268-77.Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005; 37 (1): 2-12.Edgley A.J, Krum H, Kelly D.J. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther 2012; 30 (1): e30-40.Zammit S.C, Cox A.J, Gow R.M et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009; 19 (24): 7003-6.Abdulhalim Jamal, Kinsara Yasser, Mansour Ismail. Metformin in heart failure patients. Indian Heart Journal 2018; 70 (1): 175-6.Evans J.M, Doney A.S., AlZadjali M.A. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010; 106 (7): 1006-10.